Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study

• Published in: Annals of the rheumatic diseases
• Main Authors: Brunner, Hermine I, Akikusa, Jonathan D, Al-Abadi, Eslam, Bohnsack, John F, Boteanu, Alina Lucica, Chedeville, Gaelle, Cuttica, Ruben, De La Pena, Wendy, Jung, Lawrence, Kasapcopur, Ozgur, Kobusinska, Katarzyna, Schulert, Grant S, Neiva, Claudia, Rivas-Chacon, Rafael, Rizo Rodriguez, Juan Cruz, Vazquez-Del Mercado, Monica, Wagner-Weiner, Linda, Weiss, Jennifer E, Wouters, Carine, Posner, Holly, Wouters, Ann, Chang, Cheng, White, Claire, Kanik, Keith, Liu, Shixue, Martini, Alberto, Lovell, Daniel J, Ruperto, Nicolino
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd and European League Against Rheumatism 07.06.2024
• Subjects: Antirheumatic Agents; Arthritis, Juvenile; Paediatric rheumatology; Therapeutics; Antirheumatic Agents; Arthritis, Juvenile; Therapeutics

ObjectivesWe report the safety, tolerability and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) in an ongoing long-term extension (LTE) study.MethodsPatients (2–<18 years) with JIA who completed phase 1/3 index studies or discontinued for reasons excluding treatment-...